The NCI SBIR Innovative Concept Award is a funding opportunity supporting biotech innovations focused on early-stage, high-risk/high-reward projects targeting rare and pediatric cancers. It provides up to $300,000 contract funding for typically one-year projects, requiring no preliminary data but with scientific feasibility. Eligible technology types include therapeutics, preventative agents, devices, diagnostics, and digital health technologies that can impact detection, treatment, prevention, or care of rare pediatric cancers. Late-stage development and non-exempt human subject research are out of scope.
Small businesses working on early-stage projects focused on rare and pediatric cancers; technology types include therapeutics, preventative agents, devices, diagnostics, digital health technologies; scientific feasibility required but no preliminary data necessary; excludes later stage development and non-exempt human subject research.
